Hypoglycemia induces tau hyperphosphorylation

Current Alzheimer Research

Volumn 10, Issue 3, 2013, Pages 298-308

  Lee, Chu Wan ^a   Shih, Yao Hsiang ^a   Wu, Shih Ying ^a   Yang, Tingting ^b   Lin, Chingju ^c   Kuo, Yu Min ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Akt; Alzheimer's disease; AMPK; GSK3; Hypoglycemia; Tau

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 2; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE B; PYRUVIC ACID; STREPTOZOCIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN REGION; BRAIN VENTRICLE; BRAIN WEIGHT; CELL CULTURE; CELL DIFFERENTIATION; ENZYME ACTIVATION; GLIOSIS; GLUCOSE TRANSPORT; HIPPOCAMPUS; HYPOGLYCEMIA; LEARNING; MAZE TEST; MEMORY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; RAT; SPATIAL LEARNING;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CELL LINE, TUMOR; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; HYPOGLYCEMIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MAZE LEARNING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; PHOSPHORYLATION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84876864136     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310030009     Document Type: Article

References (84)

1. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 9: 151-3 (2006).
2. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-5 (1992).
3. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease. Neurology 68: 501-8 (2007).
4. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci 30: 2088-101 (2010).
5. Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, et al. Amyloid-AA--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol 69: 709-13 (2012).
6. Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, et al. Amyloid-AAAassociated volume loss occurs only in the presence of phospho-tau. Ann Neurol 70: 657-61 (2011).
7. Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer's disease related cortical lesions. J Neural Transm Suppl 54: 97-106 (1998).
8. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70: 960-9 (2011).
9. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109: 813-36 (2002).
10. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33: 1152-62 (2002).
11. Skoog I. Vascular aspects in Alzheimer's disease. J Neural Transm Suppl 59: 37-43 (2000).
12. Schmidt R, Schmidt H, Fazekas F. Vascular risk factors in dementia. J Neurol 247: 81-7 (2000).
13. Casserly IP, Topol EJ. Convergence of atherosclerosis and alzheimer's disease: Cholesterol, inflammation, and misfolded proteins. Discov Med 4: 149-56 (2004).
14. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76: 1485-91 (2011).
15. de la Torre JC, Stefano GB. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev 34: 119-36 (2000).
16. de la Torre JC. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord 14 Suppl 1: S72-81 (2000).
17. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184-90 (2004).
18. Bell RD, Zlokovic BV. Neurovascular mechanisms and bloodbrain barrier disorder in Alzheimer's disease. Acta Neuropathol 118: 103-13 (2009).
19. Hoyer, S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490: 115-25 (2004).
20. Mazza M, Marano G, Traversi G, Bria P, Mazza S. Primary cerebral blood flow deficiency and Alzheimer's disease: shadows and lights. J Alzheimers Dis23:375-89(2010).
21. Messier C. Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol Aging 26: 26-30 (2005).
22. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 1147: 180-95 (2008).
23. de la Monte SM, Tong M, Lester-Coll N, Plater JM, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. J Alzheimers Dis 10: 89-109 (2006).
24. Schubert D. Glucose metabolism and Alzheimer's disease. Ageing Res Rev 4: 240-57 (2005).
25. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk. Neurology 76: 1568-74 (2011).
26. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6: 551-9 (2010).
27. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154: 635-41 (2001).
28. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology 75: 1195-202 (2010).
29. Craft S. Insulin resistance syndrome and Alzheimer's disease: Ageand obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26: 65-9 (2005).
30. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev 10: 264-73 (2011).
31. Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, et al. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. Dement Geriatr Cogn Disord 30: 285-92 (2010).
32. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795-804 (2012).
33. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging 35: 2169-81 (2008).
34. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chem 265: 18035-40 (1990).
35. Vannucci SJ, Maher F, Simpson IA. Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 21: 2-21 (1997).
36. Arluison M, Quignon M, Nguyen P, Thorens B, Leloup C, Penicaud L. Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain--an immunohistochemical study. J Chem Neuroanat 28: 117-36 (2004).
37. Marty N, Dallaporta M, Foretz M, Emery M, Tarussio D, Bady I, et al. Regulation of glucagon secretion by glucose transporter type 2 (glut2) and astrocyte-dependent glucose sensors. J Clin Invest 115: 3545-53 (2005).
38. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582: 359-64 (2008).
39. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX. Dysregulation of insulin signaling, glucose transporters, OGlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer's disease. Am J Pathol 175: 2089-98 (2009).
40. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase--development of the energy sensor concept. J Physiol 574: 7-15 (2006).
41. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 246: 259-73 (1997).
42. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50: 536-46 (2001).
43. Arluison M, Quignon M, Nguyen P, Thorens B, Leloup C, Penicaud L. Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain--an immunohistochemical study. J Chem Neuroanat 28: 117-36 (2004).
44. Yang T-T, Hsu C-T, Kuo Y-M. Amyloid precursor protein, heatshock proteins, and Bcl-2 form a complex in mitochondria and modulate mitochondria function and apoptosis in N2a cells. Mech Ageing Dev 130: 592-601 (2009).
45. Halestrap AP, Woodfield K-Y, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem 272: 3346-54 (1997).
46. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27: 13635-48 (2007).
47. Wu C, Liao P, Yu L, Wang S, Chen S, Kuo Y. Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits. Neurobiol Dis 17: 367-77 (2004).
48. Augustinack JC, Schneider A, Mandelkow E, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002: 26-35 (2002).
49. Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J 23: 2586-96 (2004).
50. de la Torre JC. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res 26: 517-24 (2004).
51. de la Torre JC. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann NY Acad Sci 924: 136-52 (2000).
52. Liu Y, Liu F, Iqbal K, Grundkeiqbal I, Gong C. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582: 359-64 (2008).
53. Yanagisawa M, Planel E, Ishiguro K, Fujita SC. Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease. FEBS Lett 461: 329-33. (1999).
54. Yoshida H, Goedert M. Phosphorylation of microtubule-associated protein tau by AMPK-related kinases. J Neurochem 120: 165-76 (2012).
55. Thornton C, Bright NJ, Sastre M, Muckett PJ, Carling D. AMPactivated protein kinase (AMPK) is a tau kinase, activated in response to amyloid rr-peptide exposure. Biochem J 434: 503-12 (2011).
56. Vingtdeux V, Davies P, Dickson DW, Marambaud P. AMPK is abnormally activated in tangle-and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol 121: 337-49 (2011).
57. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 89: 1025-78 (2009).
58. Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M. AMP-activated protein kinase: a potential player in Alzheimer's disease. J Neurochem 118: 460-74 (2011).
59. Kaytor MD, Orr HT. The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 12: 275-8 (2002).
60. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20: 27-39 (2001).
61. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 77: 94-102 (2001).
62. Wagner U, Utton M, Gallo JM, Miller CC. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 109 (Pt 6): 1537-43 (1996).
63. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104: 1433-9 (2008).
64. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 64: 1930-44 (2007).
65. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12: 803-8 (1993).
66. Liang MH, Chuang DM. Regulation and function of glycogen synthases kinase-3 isoforms in neuronal survival. J Biol Chem 282: 3904-17 (2007).
67. King TD, Song L, Jope RS. AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinases-3. Biochem Pharmacol 71: 1637-47 (2006).
68. Kim KY, Baek A, Hwang JE, Choi YA, Jeong J, Lee MS, et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 69: 4018-26 (2009).
69. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 9: 691-700 (2009).
70. Agrawal R, Mishra B, Tyagi E, Nath C, Shukla R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 61: 247-52 (2010).
71. Grunblatt E, Koutsilieri E, Hoyer S, Riederer P. Gene expression alterations in brain areas of intracerebroventricular STZ in treated rat. J Alzheimers Dis 9: 261-71 (2006).
72. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9: 13-33 (2006).
73. Nitsch R, Hoyer S. Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett 128: 199-202 (1991).
74. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P. Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem 96: 1005-15 (2006).
75. Rossini AA. Studies of streptozotocin-induced insulitis and diabetes. Proc Natl Acad Sci USA 74: 2485-9 (1977).
76. Blondel O, Portha B. Early appearance of in vivo insulin resistance in adult streptozotocin-injected rats. Diabete Metab 15: 382-7 (1989).
77. Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101: 757-70 (2007).
78. Grunblatt E, Hoyer S, Riederer P. Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. J Neural Transm 111: 367-86 (2004).
79. Duelli R, Schrok H, Kuschinsky W, Hoyer S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci 12: 737-43 (1994).
80. Nitsch R, Mayer G, Hoyer S. The intracerebroventriculary streptozotocin-treated rat: impairment of cerebral glucose metabolism resembles the alterations of carbohydrate metabolism of the brain in Alzheimer's disease. J Neural Transm 1: 109-10 (1989).
81. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112: 1199-208 (1998).
82. Pinton S, da Rocha JT, Gai BM, Nogueira CW. Sporadic dementia of Alzheimer's type induced by streptozotocin promotes anxiogenic behavior in mice. Behav Brain Res 223: 1-6 (2011).
83. Labak M, Foniok T, Kirk D, Rushforth D, Tomanek B, Jasinski A, et al. Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. Acta Neurochir Suppl 106: 177-81 (2010).
84. Morgello S, Uson RR, Schwartz EJ, Haber RS. The human bloodbrain barrier glucose transporter (GLUT1) is a glucose transporter of gray matter astrocytes. Glia 14: 43-54 (1995).